Bristol Myers Squibb Completes Sale of Manufacturing Facility in Couvet, Switzerland
Bristol Myers Squibb (NYSE: BMY) has finalized the sale of its manufacturing facility in Couvet, Switzerland, to WuXi STA, a subsidiary of WuXi AppTec. This divestiture is part of the company's strategic evolution of its manufacturing network to better align with its product portfolio. The Couvet site, known for its state-of-the-art commercial-scale production capabilities, will allow BMY to focus on its core operations while maintaining a significant presence in Switzerland.
- Strategic divestiture to enhance manufacturing efficiency.
- State-of-the-art production facility sold to a reputable company, WuXi STA.
- Potential loss of direct control over the Couvet facility's operations.
Bristol Myers Squibb (NYSE: BMY) today announced that it has completed the previously announced sale of its manufacturing facility in Couvet, Switzerland, to WuXi STA, a subsidiary of WuXi AppTec.
The divestiture is part of Bristol Myers Squibb’s ongoing evolution of its manufacturing network to support its product portfolio. Switzerland remains an important strategic location for the Company, and Bristol Myers Squibb expects to maintain a strong presence in the country.
The Couvet site is located in the canton of Neuchâtel, Switzerland. The site is a state-of-the-art manufacturing facility with commercial-scale production capacity for capsule and tablet dosage forms.
About Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook and Instagram.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the research, development and commercialization of pharmaceutical products and the transaction. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements are based on historical performance and current expectations and projections about our future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond our control and could cause our future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. These risks, assumptions, uncertainties and other factors include, among others, any delay or inability of Bristol Myers Squibb to realize the expected benefits of the transaction. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol Myers Squibb’s business and market, particularly those identified in the cautionary statement and risk factors discussion in Bristol Myers Squibb’s Annual Report on Form 10-K for the year ended December 31, 2020, as updated by our subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, Bristol Myers Squibb undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.
CorporateFinancial-News
View source version on businesswire.com: https://www.businesswire.com/news/home/20210803005191/en/
FAQ
What recent transaction did Bristol Myers Squibb (BMY) complete?
What is the reason behind Bristol Myers Squibb's sale of its facility?
What type of production is the Couvet facility known for?
Will Bristol Myers Squibb maintain a presence in Switzerland after the sale?
